Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies / Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies // J. Peripher. Nerv. Syst. — 2010. — Vol. 15. — P. 185-195.
Steck AJ, Erne B, Gabriel JM, Schaeren-Wiemers N. Paraproteinaemic neuropathies. Brain Pathol. 1999;9(2):361-368. doi:10.1111/j.1750-3639.1999.tb00232.x
Nobile-Orazio E. Neuropathy and monoclonal gammopathy. Handb Clin Neurol. 2013;115:443-459. doi:10.1016/B978-0-444-52902-2.00025-4
Kelly JJ. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance. Rev Neurol Dis. 2008;5(1):14-22.
Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12(1):102-110. doi:10.1007/s11910-011-0237-4
Viera S, Ludek P, Zdeněk A, et al. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS). Monoklonální gamapatie nejasného významu (MGUS). Klin Onkol. 2018;31(4):270-276. doi:10.14735/amko2018270
Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clin Proc. 2017;92(5):838-850. doi:10.1016/j.mayocp.2017.02.003
van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. Cancer Res. 2018;78(10):2449-2456. doi:10.1158/0008-5472.CAN-17-3115
Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995;37 Suppl 1:S32-S42. doi:10.1002/ana.410370705
Rinaldi S, Bennett DL. Pathogenic mechanisms in inflammatory and paraproteinaemic peripheral neuropathies. Curr Opin Neurol. 2014;27(5):541-551. doi:10.1097/WCO.0000000000000137
Dalakas M.C. Pathogenesis and treatment of Anti-MAG neuropathy // Curr. Treat. Options Neurol. — 2010. — Vol. 12. — P. 71-83.
Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369. doi:10.1056/NEJMoa054494
Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85(10):933-942. doi:10.4065/mcp.2010.0337
Ma L, Xu S, Qu J, et al. Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. Hematol Oncol. 2019;37(1):75-79. doi:10.1002/hon.2548
Onwah AL, Adeyemo TA, Adediran A, Ajibola SO, Akanmu AS. Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study. BMC Blood Disord. 2012;12:7. Published 2012 Jun 28. doi:10.1186/1471-2326-12-7
Park HK, Lee KR, Kim YJ, et al. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. Am J Hematol. 2011;86(9):752-755. doi:10.1002/ajh.22095
Eisele L, Dürig J, Hüttmann A, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012;91(2):243-248. doi:10.1007/s00277-011-1293-1
Kyle R., Therneau T. A long-term study of prognosis in monoclonal gammopathy of undetermined significance // N. Engl. J. Med. — 2002. — Vol. 346. — P. 564-569. - 1384.
Steiner N, Schwärzler A, Göbel G, Löscher W, Wanschitz J, Gunsilius E. Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?. Oncotarget. 2017;8(3):5081-5091. doi:10.18632/oncotarget.13861
Sabatelli M, Laurenti L, Luigetti M. Peripheral Nervous System Involvement in Lymphoproliferative Disorders. Mediterr J Hematol Infect Dis. 2018;10(1):e2018057. Published 2018 Sep 1. doi:10.4084/MJHID.2018.057
Kyle R. Diagnostic criteria of multiple myeloma // Hematol. Oncol. Clin. N. Am. — 1992. — Vol. 6. — P. 347-358. - 787
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
Van den Bergh P.Y., Hadden R.D., Bouche P. et al. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision // J Peripher Nerv Syst. - 2010. - №.15. - С. 1–9.
Lehmann H. C., Burke D., Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment //J Neurol Neurosurg Psychiatry. 2019. С. jnnp-2019-320314.
Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology. 1992;42(6):1157-1163. doi:10.1212/wnl.42.6.1157
Cocito D, Durelli L, Isoardo G. Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinaemia. Acta Neurol Scand. 2003;108(4):274- 280. doi:10.1034/j.1600-0404.2003.00127.x
Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris). 2002;158(10 Pt 1):979-987.
Gao XM, Jia MN, Qian M, et al. Anti-myelin-associated Glycoprotein Antibody Positive IgM Monoclonal Gammopathy Related Peripheral Neuropathy: 11 Cases and Literature Review. Zhonghua Xue Ye Xue Za Zhi. 2019;40(11):901-905. doi:10.3760/cma.j.issn.0253- 2727.2019.11.003
Stork AC, van der Pol WL, Franssen H, Jacobs BC, Notermans NC. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol. 2014;261(7):1398-1404. doi:10.1007/s00415-014-7354- 3